Revolution Medicines, Inc. (RVMD)
NASDAQ: RVMD · Real-Time Price · USD
206.97
+1.82 (0.89%)
At close: Aug 10, 2026, 4:00 PM EDT
205.46
-1.51 (-0.73%)
Pre-market: Aug 11, 2026, 5:24 AM EDT
Revolution Medicines Stock Forecast
Stock Price Forecast
According to 22 analysts polled by S&P Global, Revolution Medicines stock has a consensus rating of "Strong Buy" and an average price target of $220.81. The average 1-year stock price forecast is 6.69% higher than the current stock price, while the lowest is $151 (-27.04%) and the highest is $291 (+40.60%).
Price Target: $220.81 (+6.69%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Revolution Medicines stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 17 | 17 | 17 | 17 | 17 | 17 |
| Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Hold | 0 | 0 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 21 | 21 | 22 | 22 | 22 | 22 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wolfe Research | Wolfe Research | Buy Maintains $165 → $220 | Buy | Maintains | $165 → $220 | +6.30% | Aug 10, 2026 |
| TD Cowen | TD Cowen | Buy Reiterates $205 | Buy | Reiterates | $205 | -0.88% | Aug 10, 2026 |
| LifeSci Capital | LifeSci Capital | Buy Maintains $263 → $291 | Buy | Maintains | $263 → $291 | +40.60% | Aug 8, 2026 |
| J.P. Morgan | J.P. Morgan | Buy Maintains $205 → $227 | Buy | Maintains | $205 → $227 | +9.68% | Aug 7, 2026 |
| Stifel Nicolaus | Stifel Nicolaus | Buy Maintains $215 | Buy | Maintains | $215 | +3.88% | Aug 6, 2026 |
Financial Forecast
Revenue This Year
126.91M
Revenue Next Year
967.62M
from 126.91M
Increased by 662.47%
EPS This Year
-8.87
from -5.95
EPS Next Year
-5.95
from -8.87
EPS and Forward PE are based on non-GAAP adjusted numbers.